Displaying 41–50 of 305 research results
Jul 22, 2022
There are currently no FDA-approved therapies for geographic atrophy (GA), the advanced form of dry AMD.
Jul 14, 2022
The emerging treatment is gene-agnostic.
Jun 27, 2022
The approach bestows light sensitivity to retinal ganglion cells for people who have lost their photoreceptors
Jun 20, 2022
The newly approved drug reduces the pathologic hunger associated with BBS
Jun 13, 2022
In its seventh year, the Retinal Cell & Gene Therapy Innovation Summit featured 34 presentations from industry experts from around the world.
May 24, 2022
The company’s RPESC-RPE cell product is composed of progenitor-stage RPE cells grown from human eyes donated to eye banks.
May 19, 2022
However, the Phase 2/3 Illuminate trial for sepofarsen didn’t meet its endpoints at 12 months
May 17, 2022
The three-month results support the planned launch of the company’s Phase 2/3 Vista trial
May 13, 2022
The device is designed for people with late-stage AMD who have no treatment options
May 9, 2022
Editas is planning IND-enabling studies of the two-part treatment in preparation for a clinical trial